

Optical Resolution of Racemic 4-Hydroxy-3-isobornyl-5-methylbenzaldehyde

E. V. Buravlev^a, I. Yu. Chukicheva^a, A. V. Churakov^b, and A. V. Kutchin^a

^a Institute of Chemistry, Komi Research Center, Ural Division, Russian Academy of Sciences, ul. Pervomaiskaya 48, Syktyvkar, 167982 Russia
e-mail: buravlev-ev@chemi.komisc.ru

^b Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Moscow, Russia

Received May 30, 2011

Abstract—Racemic 4-hydroxy-3-isobornyl-5-methylbenzaldehyde was separated into particular enantiomers via transformation into diastereoisomeric Schiff bases by reaction with (*R*)-1-phenylethanamine. The absolute configuration of the products was determined on the basis of the X-ray diffraction data for camphanate derived from one enantiomer of 4-hydroxy-3-isobornyl-5-methylbenzaldehyde.


DOI: 10.1134/S1070428012010095

The presence of an aldehyde group in the molecules of 4-hydroxy-3,5-dialkylbenzaldehydes opens prospects in the synthesis of porphyrins [1] and fused, heterocyclic [2–4], and phosphorus-containing compounds [5] functionalized by 2,4-dialkylphenol fragments. These compounds attract interest from the viewpoint of their physiological and antioxidant properties. Racemic phenols having an isobornyl substituent

are synthetically accessible, they possess anti-thrombogenic and antithrombotic properties [6] and can be used as antioxidants [7]. It is desirable that both racemic and optically active derivatives of isobornyl-phenols be available to study their biological activity.

We previously reported on optical resolution of racemic salicylaldehydes having an isobornyl substituent with the use of (*R*)-1-phenylethanamine [8]. The


Scheme 1.



present article reports on the synthesis and optical resolution of racemic isobornylphenol possessing an aldehyde group in the *para* position with respect to the hydroxy group. Isobornylphenol *rac*-**I** was synthesized by alkylation of *o*-cresol with camphene in the presence of aluminum methylphenoxide [7]. The corresponding aldehyde *rac*-**II** was prepared by treatment of *rac*-**I** with hexamethylenetetramine (urotropin) in acetic acid (Duff reaction) according to the procedure described in [9]. Racemate **II** was separated into individual enantiomers via transformation into diastereoisomeric Schiff bases by reaction with enantiomerically pure (*R*)-1-phenylethanamine (Scheme 1). The Schiff bases were obtained in quantitative yield as mixtures of diastereoisomers **III** and **IV** at a ratio of ~1:1 (GLC data). By fractional crystallization from hexane we succeeded in isolating compounds **III** and **IV** enriched in one diastereoisomer. The diastereoisomeric purity was estimated by GLC.

The NOESY spectra of **III** and **IV** revealed coupling between the 18-H and 19-H protons,* indicating that these protons are spatially close to each other. These findings suggest that Schiff bases **III** and **IV** have *E* configuration with respect to the double C=N bond. Aldehydes (+)-**II** and (–)-**II** enriched in particular enantiomer were isolated by acid hydrolysis of each Schiff base. Their optical purity was estimated by analytical HPLC on a Chiralcel OD-H column.

Scheme 2.



Ester **V** was synthesized by acylation of (+)-**II** at the hydroxy group with (1*S*)-camphanic chloride (Scheme 2). Slow evaporation of a solution of **V** in hexane–diethyl ether gave single crystals suitable for X-ray analysis (see figure). According to the X-ray diffraction data, compound **V** crystallized in *P*2₁ chiral space group. The bond lengths and bond angles in molecule **V** were similar to those found previously for


* For atom numbering, see Schemes 1 and 2.

other isobornylphenol derivatives [10]. However, the conformation of **V** differed considerably from that typical of structurally related compounds. The torsion angle C⁶C¹C²²C²¹ in molecule **V** is –149.2(2)° against –79.8(3) to –82.6(3)° reported in [10] for analogous compounds. Some selected geometric parameters of molecule **V** in crystal are collected in table.

The absolute configuration of compound **V** was determined on the basis of anomalous X-ray scattering; it coincided with the relative configuration assumed from the known configuration of the camphane substituent. The chiral centers in the isobornyl fragment of (+)-**II**, **IV**, and **V** have (1*R*,2*S*,4*S*) configuration. The configuration of the terpene fragment in compounds **III** and (–)-**II** is the opposite, (1*S*,2*R*,4*R*).

EXPERIMENTAL

The IR spectra were recorded in KBr on a Specord M-80 spectrometer. The ¹H and ¹³C NMR spectra were measured on a Bruker Avance II 300 spectrometer (300.17 and 75.48 MHz, respectively) from solutions in CDCl₃. The chemical shifts were determined relative to the solvent signals (δ 7.26 ppm, δ_C 77.00 ppm). Signals were assigned on the basis of *J*-modulation ¹³C NMR spectra and two-dimensional spectra (HSQC, COSY, NOESY). The melting points were determined on a Kofler hot stage. The optical rotations were measured using a P3002RS Krüss Optronic automatic digital polarimeter (λ 589 nm).



Structure of the molecule of 4-formyl-2-methyl-6-((1*R*,2*S*,4*S*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)phenyl (1*S*,4*R*)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (**V**) according to the X-ray diffraction data.

Selected bond lengths and bond angles in the molecule of 4-formyl-2-methyl-6- $\{(1R,2S,4S)\}$ -1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl]phenyl (1*S*,4*R*)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (**V**)

Bond	<i>d</i> , Å	Angle	ω , deg
O ¹ –C ²⁰	1.350(2)	C ²⁰ O ¹ C ²¹	116.52(14)
O ¹ –C ²¹	1.412(2)	C ¹¹ O ³ C ¹⁵	105.92(14)
O ² –C ²⁰	1.203(2)	O ⁴ C ¹¹ O ³	121.47(19)
O ³ –C ¹¹	1.372(2)	O ⁴ C ¹¹ C ¹²	131.22(18)
O ³ –C ¹⁵	1.470(2)	O ³ C ¹¹ C ¹²	107.30(16)
O ⁴ –C ¹¹	1.200(2)	O ² C ²⁰ O ¹	124.40(19)
O ⁵ –C ²⁷	1.226(3)	O ² C ²⁰ C ¹⁵	125.01(18)
		O ¹ C ²⁰ C ¹⁵	110.55(16)
		O ⁵ C ²⁷ C ²⁴	124.1(2)

The progress of reactions was monitored by TLC on Sorbfil plates. Aldehyde spots were detected by treatment with a solution of 15 g of potassium permanganate in 300 ml of water containing 0.5 ml of concentrated sulfuric acid. Ester **V** was detected by treatment with a solution of Bromocresol Purple, followed by heating to 100–120°C. The purity of phenol **I** and aldehydes **II** was checked by GLC on a Shimadzu GC-2010AF gas chromatograph equipped with a flame-ionization detector (carrier gas helium; Agilent HP-1 capillary column, 60 m \times 0.25 mm \times 0.25 μ m; oven temperature programming from 100 to 240°C at a rate of 6 deg/min); diastereoisomeric purity of Schiff bases **III** and **IV** was determined at an oven temperature of 270°C. Enantiomeric purity of aldehydes **II** was estimated by HPLC on an Agilent 1100 chromatograph [UV detector, λ 224 nm; 20°C; Chiralcel OD-H column (Daicel), 25 cm \times 4.6 mm, 10 μ m, eluent hexane-*i*-PrOH (19:1), flow rate 1.0 ml/min].

Aldehydes **II** and ester **V** were purified by column chromatography on silica gel Alfa Aesar 70/230 μ (wet packing). Toluene was dried over anhydrous CaCl₂ and was distilled over metallic sodium. Petroleum ether with bp 65–70°C was used. Hexane was distilled just before use. Molecular sieves (4 Å) were activated by calcination at 140°C over a period of 3 h. (*R*)-(+)-1-Phenylethylamine (Alfa Aesar, ChiPros®, enantiomeric purity >99%), (1*S*)-camphanic acid chloride (Acros Organics), triethylamine (Sigma–Aldrich), 4-dimethylaminopyridine, urotropin, acetic acid, and diethyl ether of chemically pure grade were used without additional purification.

X-Ray analysis was performed for a 0.15 \times 0.15 \times 0.10-mm single crystal of ester **V** on a Bruker Smart

Proteum automatic diffractometer with a rotating anode at 100.0(2) K (CuK α irradiation, λ 1.54178 Å, graphite monochromator). Monoclinic crystals (C₂₈H₃₆O₅, *M* 452.57), space group *P*2₁, with the following unit cell parameters: *a* = 7.9126(2), *b* = 7.0320(1), *c* = 21.4735(5) Å; β = 93.661(1)°; *V* = 1192.38(4) Å³; *Z* = 2; *d*_{calc} = 1.261 g/cm³; μ (CuK α) = 0.681 mm⁻¹; *F*(000) = 488. Total of 7933 reflections (3361 independent reflections with *R*_{int} = 0.0345) were measured by ϕ - and ω -scanning through a step of 0.5° in the range 2.06 < θ < 63.03° (–9 \leq *h* \leq 8, –7 \leq *k* \leq 8, –22 \leq *l* \leq 24). Correction for absorption was introduced by measuring the intensities of equivalent reflections (transmission factors min/max = 0.905/0.935). The structure was solved by the direct method and was refined by the full-matrix least-squares procedure in anisotropic approximation with respect to *F*² for all non-hydrogen atoms (SHELXTL-PLUS [11]). All hydrogen atoms were placed into positions calculated on the basis of geometry considerations and were refined according to the riding model. The final divergence factors were *R*₁ = 0.0350, *wR*₂ = 0.0922 for 3303 reflections with *I* > 2 σ (*I*) and *R*₁ = 0.0355, *wR*₂ = 0.0927 (for all reflections); 305 refined parameters; absolute structure parameter –0.12(17); goodness of fit 1.046; $\Delta\rho_{\text{min/max}}$ = –0.191/0.319.

4-Hydroxy-3-methyl-5-(1,7,7-trimethylbicyclo[2.2.1]heptan-*exo*-2-yl)benzaldehyde (*rac*-II**).** A mixture of 3.2 g (13.1 mmol) of phenol *rac*-**I**, 1.47 g (10.5 mmol) of urotropin, and 8 ml of 90% aqueous acetic acid was heated for 3 h under reflux. The progress of the reaction was monitored by thin-layer chromatography using petroleum ether–diethyl ether (5:1) as eluent. The precipitate was filtered off, dried, and purified by column chromatography (gradient elution with petroleum ether–diethyl ether). Yield 2.6 g (73%), colorless powder, mp 155–157°C (from petroleum ether). IR spectrum, ν , cm⁻¹: 3232 (OH), 1674 (C=O). ¹H NMR spectrum, δ , ppm: 0.78 s (3H, C¹⁰H₃), 0.85 s (3H, C⁹H₃), 0.89 s (3H, C⁸H₃), 1.45–1.49 m (1H, 5-H), 1.59–1.73 m (3H, 3-H, 6-H), 1.78–1.95 m (2H, 4-H, 5-H), 2.32–2.46 m (1H, 3-H), 2.32 s (3H, C¹⁷H₃), 3.07 t (1H, 2-H, *J* = 8.8 Hz), 5.37 s (1H, OH), 7.53 br.s and 7.73 br.s (1H each, 14-H, 16-H), 9.82 s (1H, 18-H). ¹³C NMR spectrum, δ_c , ppm: 12.42 (C¹⁰), 16.17 (C¹⁷), 20.33 (C⁹), 21.30 (C⁸), 27.46 (C⁵), 34.21 (C³), 40.01 (C⁶), 45.45 (C⁴), 45.65 (C²), 48.23 (C⁷), 49.83 (C¹); 123.52, 128.80, 129.99 (C¹¹, C¹³, C¹⁵); 128.68, 130.39 (C¹⁴, C¹⁶); 159.07 (C¹²), 191.66 (C¹⁸). Found, %: C 79.12; H 8.97. C₁₈H₂₄O₂. Calculated, %: C 79.37; H 8.88.

Enantiomerically enriched aldehydes II. A mixture of 0.3 g (0.8 mmol) of Schiff base **III** or **IV** and 5 ml of 90% aqueous acetic acid was heated for 2.5 h under reflux, 10 ml of diethyl ether was added, the organic layer was separated, washed with water (2 × 7 ml) to remove acid, dried over anhydrous sodium sulfate, and evaporated. The residue was purified by column chromatography using petroleum ether–diethyl ether as eluent.

4-Hydroxy-3-methyl-5-((1*S*,2*R*,4*R*)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)benzaldehyde (–)(II). Yield 0.18 g (82%), enantiomeric purity 60.8%. Retention time 9.53 min. Colorless powder, mp 139–140°C (from petroleum ether), $[\alpha]_D^{23} = -28.3^\circ$ ($c = 0.3$, CHCl₃).

4-Hydroxy-3-methyl-5-((1*R*,2*S*,4*S*)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)benzaldehyde (+)(II). Yield 0.19 g (86%), enantiomeric purity 85.4%. Retention time 10.56 min. Colorless powder, mp 140–142°C (from petroleum ether), $[\alpha]_D^{23} = +49.4^\circ$ ($c = 0.3$, CHCl₃).

Schiff bases III and IV. A mixture of 1.5 g (5.5 mmol) of racemic aldehyde **II** dissolved in 25 ml of toluene, 0.71 ml (5.5 mmol) of (*R*)-(+)-1-phenylethanamine and 6.5 g of molecular sieves was heated for 3.5 h under reflux while stirring in a stream of argon. The mixture was filtered through a glass filter, the precipitate (molecular sieves) was washed with CHCl₃, and the filtrate was evaporated. The residue was separated by fractional crystallization from hexane, the separation process being monitored by GLC.

2-Methyl-6-((1*S*,2*R*,4*R*)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-4-((*E*)-[(*R*)-1-phenylethylimino]methyl)phenol (III). Yield 0.4 g (19%), diastereoisomeric purity 63%. Retention time 20.1 min. Brown powder, mp 64–69°C (from hexane). IR spectrum, ν , cm⁻¹: 3408 (OH), 1640 (C=N). ¹H NMR spectrum, δ , ppm: 0.79 s (3H, C¹⁰H₃), 0.86 s (3H, C⁹H₃), 0.87 s (3H, C⁸H₃), 1.28–1.52 m (2H, 5-H, 6-H), 1.59 d (3H, C²⁰H₃, $J = 6.6$ Hz), 1.60–1.73 m (2H, 3-H, 6-H), 1.82–1.96 m (2H, 4-H, 5-H), 2.19–2.34 m (1H, 3-H), 2.26 s (3H, C¹⁷H₃), 3.09 t (1H, 2-H, $J = 8.7$ Hz), 4.50 q (1H, 19-H, $J = 6.6$ Hz), 5.06 br.s (1H, OH), 7.21–7.59 m (7H, 14-H, 16-H, 22-H, 22'-H, 23-H, 23'-H, 24-H), 8.26 br.s (1H, 18-H). ¹³C NMR spectrum, δ_C , ppm: 12.38 (C¹⁰), 16.11 (C¹⁷), 20.37 (C⁹), 21.38 (C⁸), 24.80 (C²⁰), 27.52 (C⁵), 34.20 (C³), 40.05 (C⁶), 45.52 (C⁴), 45.73 (C²), 48.17 (C⁷), 49.78 (C¹), 69.52 (C¹⁹), 123.34 (C¹³), 126.63 and 128.32 (C²², C^{22'}, C²³, C^{23'}, C²⁴), 127.06 and 127.76 (C¹⁴, C¹⁶), 128.22 (C¹⁵), 128.81

(C¹¹), 145.64 (C²¹), 155.45 (C¹²), 159.59 (C¹⁸). Found, %: C 83.31; H 8.93; N 3.87. C₂₆H₃₃NO. Calculated, %: C 83.15; H 8.86; N 3.73.

2-Methyl-6-((1*R*,2*S*,4*S*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)-4-((*E*)-[(*R*)-1-phenylethylimino]methyl)phenol (IV). Yield 0.71 g (34%), diastereoisomeric purity 86%. Retention time 20.2 min. Light yellow powder, mp 127–129°C (from hexane). IR spectrum, ν , cm⁻¹: 3396 (OH), 1642 (C=N). ¹H NMR spectrum, δ , ppm: 0.79 s (3H, C¹⁰H₃), 0.86 s (3H, C⁹H₃), 0.93 s (3H, C⁸H₃), 1.33–1.49 m (2H, 5-H, 6-H), 1.59 d (3H, C²⁰H₃, $J = 6.6$ Hz), 1.62–1.72 m (2H, 3-H, 6-H), 1.81–1.96 m (2H, 4-H, 5-H), 2.20–2.32 m (1H, 3-H), 2.27 s (3H, C¹⁷H₃), 3.09 t (1H, 2-H, $J = 8.7$ Hz), 4.51 q (1H, 19-H, $J = 6.6$ Hz), 4.98 br.s (1H, OH), 7.20–7.54 m (7H, 14-H, 16-H, 22-H, 22'-H, 23-H, 23'-H, 24-H), 8.26 br.s (1H, 18-H). ¹³C NMR spectrum, δ_C , ppm: 12.39 (C¹⁰), 16.08 (C¹⁷), 20.34 (C⁹), 21.43 (C⁸), 24.86 (C²⁰), 27.56 (C⁵), 34.28 (C³), 40.13 (C⁶), 45.59 (C⁴), 45.81 (C²), 48.22 (C⁷), 49.83 (C¹), 69.48 (C¹⁹), 123.17 (C¹³), 126.61 and 128.32 (C²², C^{22'}, C²³, C^{23'}, C²⁴), 127.23 and 127.57 (C¹⁴, C¹⁶), 128.20 (C¹⁵), 128.81 (C¹¹), 145.59 (C²¹), 155.45 (C¹²), 159.63 (C¹⁸). Found, %: C 83.34; H 9.01; N 3.61. C₂₆H₃₃NO. Calculated, %: C 83.15; H 8.86; N 3.73.

4-Formyl-2-methyl-6-((1*R*,2*S*,4*S*)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)phenyl (1*S*,4*R*)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (V). A mixture of 0.027 g (0.1 mmol) of aldehyde (+)-II dissolved in 3 ml of toluene, 0.032 g (0.15 mmol) of (1*S*)-camphanic acid chloride, 0.021 ml (0.15 mmol) of triethylamine, and 0.0012 g (0.01 mmol) of 4-dimethylaminopyridine was heated for 4 h under reflux with stirring in a stream of argon. The mixture was evaporated, and the residue was purified by column chromatography using petroleum ether–diethyl ether as eluent. Yield 0.039 g (87%), colorless powder, mp 142–145°C (from hexane), $[\alpha]_D^{23} = +9.1^\circ$ ($c = 0.1$, CHCl₃). IR spectrum, ν , cm⁻¹: 1798, 1764 (C=O, ester), 1706 (CH=O), 1260 (C–O). ¹H NMR spectrum, δ , ppm: 0.76–1.00 m (9H, C⁸H₃, C⁹H₃, C¹⁰H₃), 1.17 s (9H, C⁸H₃, C⁹H₃, C¹⁰H₃), 1.23–1.34 m (1H, 5-H), 1.35–1.49 m (1H, 6-H), 1.58–1.91 m (5H, 3-H, 4-H, 5-H, 5'-H, 6-H), 1.96–2.05 m (1H, 5'-H), 2.20–2.31 m (2H, 3-H, 6'-H), 2.24 s (1H, C¹⁷H₃), 2.50–2.60 m (1H, 6'-H), 2.82 t (1H, 2-H, $J = 8.7$ Hz), 7.60 br.s (1H, 14-H), 7.86 s (1H, 16-H), 9.94 s (1H, 18-H). ¹³C NMR spectrum, δ_C , ppm: 9.67, 16.78, 16.95 (C⁸, C⁹, C¹⁰); 17.42 (C¹⁷), 21.30 (C⁸, C⁹, C¹⁰), 27.30 (C³, C⁵), 28.83 and 28.99 (C⁵, C⁶), 31.82 (C⁶), 45.52 (C⁴), 46.74 (C²), 48.10 (C¹, C⁷), 54.48 and 54.91

(C⁴, C⁷), 90.45 (C¹), 128.37 (C¹⁶), 130.05 (C¹⁴), 131.08 (C¹¹), 133.82 (C¹³), 156.86 (C¹²), 165.50 and 177.74 (C³, C¹¹), 191.54 (C¹⁸). Found, %: C 74.05; H 8.24. C₂₈H₃₆O₅. Calculated, %: C 74.31; H 8.02.

This study was performed under financial support by the Russian Foundation for Basic Research (project no. 10-03-01129-a) and by the Ural Division of the Russian Academy of Sciences (competition of research projects of young scientists and post-graduate students of the Ural Division of the Russian Academy of Sciences, project no. 10-3-NP-95). The authors thank the Faculty of Chemistry, Durham University (United Kingdom) for providing X-ray diffraction facilities.

REFERENCES

1. Gerasimova, O.A., Milaeva, E.R., Shpakovskii, D.B., Semeikin, A.S., and Syrbu, S.A., *Russ. Chem. Bull.*, 2007, vol. 56, p. 831.
2. Unangst, P.C., Connor, D.T., Cetenko, W.A., Sorenson, R.J., Kostlan, C.R., Sircar, J.C., Wright, C.D., Schrier, D.J., and Dyer, R.D., *J. Med. Chem.*, 1994, vol. 37, p. 322.
3. Hori, H., Nagasawa, H., Ishibashi, M., Uto, Y., Hirata, A., Saijo, K., Ohkura, K., Kork, K.L., and Uehara, Y., *Bioorg. Med. Chem.*, 2002, vol. 10, p. 3257.
4. Boldron, C., Özalp-Yaman, Ş., Gamez, P., Tooke, D.M., Spek, A.L., and Reedijk, J., *J. Chem. Soc., Dalton Trans.*, 2005, p. 3535.
5. Prishchenko, A.A., Livantsov, M.V., Novikova, O.P., Livantsova, L.I., Shpakovskii, D.B., and Milaeva, E.R., *Russ. J. Gen. Chem.*, 2006, vol. 76, p. 1753.
6. Plotnikov, M.B., Smolyakova, V.I., Ivanov, I.S., Kuchin, A.V., Chukicheva, I.Yu., Buravlev, E.V., and Krasnov, E.A., *Pharm. Chem. J.*, 2010, vol. 44, p. 530.
7. Chukicheva, I.Yu., Buravlev, E.V., Fedorova, I.V., Borisenkov, M.F., and Kutchin, A.V., *Russ. Chem. Bull.*, 2010, vol. 59, p. 2276.
8. Buravlev, E.V., Chukicheva, I.Yu., Dolgushin, F.M., and Kuchin, A.V., *Russ. J. Org. Chem.*, 2010, vol. 46, p. 649.
9. Niyazov, N.A. and Pantukh, B.I., Russian Patent no. 2063399, 1996; *Byull. Izobret.*, 1996, no. 19.
10. Buravlev, E.V., Chukicheva, I.Yu., Suponitsky, K.Yu., Vikharev, Yu.B., Grishko, V.V., and Kutchin, A.V., *Lett. Org. Chem.*, 2011, vol. 8, p. 301.
11. Sheldrick, G.M., *Acta Crystallogr., Sect. A*, 2008, vol. 64, p. 112.